Below are brief introductions to RSV disease and the RSV vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.
Respiratory Syncytial Virus (RSV) is a common and highly contagious respiratory virus that produces cold symptoms such as coughing, sneezing, wheezing, decreased appetite, fever and malaise. Most people who become infected with RSV will recover fully within a week or two without treatment.
Young infants and children, older adults, and individuals with immune system disorders and chronic health conditions are at an increased risk of RSV infection and may also be at an elevated risk of developing complications from the illness. Complications of RSV infection include inflammation of the small airways within the lungs (bronchiolitis) and lung infection (pneumonia) and may require hospitalization for supportive care.
In July 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV. Though the CDC has determined that it can define nirsevimab as a vaccine for their purposes, nirsevimab is not classified as a vaccine by the FDA, American Medical Association, or the World Health Organization. To learn about nirsevimab, visit NVIC’s RSV Prevention and Treatment page.
Three RSV vaccines are licensed for use in the US by the Food and Drug Administration (FDA). AREXVY by GlaxoSmithKline (GSK) is FDA approved for use in persons 50 years and older and MRESVIA by Moderna is FDA approved for use in individuals 60 years of age and older. ABRYSVO by Pfizer is approved for individuals 60 years of age and older and for use in pregnant women for the prevention of RSV disease in their newborns. No RSV vaccine has demonstrated the ability to prevent transmission of RSV. AREXVY RSV vaccine efficacy peaks within two months of administration, and offers no protection at one year. A booster dose of AREXVY given one year later does not offer any additional benefit.
ABRYSVO RSV vaccine is assumed to offer persistent protection for 7 months but is no longer effective by 24 months. The CDC recommends use of RSV vaccines in persons 60 through 74 years who are considered to be at high risk for severe RSV disease, and for all persons 75 years and older, to be given as a one-time single dose. RSV vaccines are also recommended for pregnant women, between 32 and 36 weeks’ gestation during the season when RSV is actively circulating.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Respiratory Syncytial Virus (RSV) and the RSV vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.